Saturday 17 October 2026
Export ALLR’s income statement to Excel — free account
Allarity Therapeutics, Inc.
ALLR Healthcare Biotechnology
Allarity Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $320,000.00. In the quarter to June 2026, EPS fell 40.0%, free cash flow grew 53.2% and total debt rose 3.56%, each against the same quarter a year earlier.
0.90
0.07
+8.43%
Follow ALLR
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | — | — |
+8 more quarters Free account |
P/S ratio |
— | 0.00 | — | — | |
P/FCF ratio |
— | 0.00 | — | — | |
P/Operating CF |
— | (3.87) | — | — | |
P/B ratio |
— | 2.52 | — | — | |
Price to Tangible BV |
— | 0.00 | — | — | |
EV/Sales |
— | 0.00 | — | — | |
EV/EBITDA |
— | 0.78 | — | — | |
EV/Operating CF |
— | 0.59 | — | — | |
EV/FCF |
— | 0.58 | — | — | |
Quick Ratio |
0.99 | 1.10 | 1.85 | 2.11 | |
Current Ratio |
1.11 | 1.23 | 2.13 | 2.33 | |
Net Debt/EBITDA |
9.69 | 10.46 | 4.11 | 6.05 | |
Debt/Assets |
4.43% | 4.05% | 7.67% | 6.68% | |
Debt/Equity |
0.40 | 0.20 | 0.14 | 0.12 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.75 | 1.63 | 0.96 | 1.22 | |
Capex/Depreciation |
0.00 | 2.46 | (1.00) | 0.00 | |
Interest Coverage |
(3.71) | (11.74) | (49.46) | (44.18) | |
Research and Development Expense of Revenue |
0.00% | 5,188.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 5,664.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 640.00% | 0.00% | 0.00% | |
Graham Net Nets |
— | 0.37 | — | — | |
Graham Number |
— | 0.00 | — | — | |
Earnings Yield |
— | (66.06%) | — | — | |
Free Cash Flow Yield |
— | (97.75%) | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.16) | (0.28) | (0.23) | (0.23) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.16) | (0.29) | (0.23) | (0.23) | |
Cash per Share |
1.70 | 1.87 | 1.02 | 1.15 | |
Shareholders Equity per Share |
0.22 | 0.43 | 0.68 | 0.81 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.22 | 0.43 | 0.68 | 0.81 | |
Free Cash Flow |
(2.56) | (4.56) | (3.25) | (3.41) | |
Working Capital |
3.15 | 6.50 | 9.50 | 11.68 | |
Capital Expenditures |
0.00 | (0.06) | (0.01) | — | |
Net Current Asset Value |
3.15 | 6.50 | 9.50 | 11.68 | |
EV/EBIT |
— | 0.80 | — | — | |
Capex to Sales |
0.00 | 2.56 | 0.00 | — | |
Price to Operating Income |
— | 0.00 | — | — | |
| Other line items | |||||
Average Receivables |
1.46 | 1.10 | 1.53 | 1.66 | |
Average Payables |
4.36 | 4.29 | 4.23 | 4.65 | |
Average Assets |
26.66 | 32.33 | 20.45 | 20.59 | |
Average Common Equity |
7.85 | 12.79 | 10.82 | 12.49 |
Columns are period end dates